UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Inquiry Search clinical trials

Name
UMIN ID

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000006909
Receipt No. R000008166
Scientific Title Prospective Surveillance for Community-Acquired Pneumonia and Healthcare-Associated Pneumonia among Japanese Adults: Multicenter Study
Date of disclosure of the study information 2011/12/31
Last modified on 2016/08/22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective Surveillance for Community-Acquired Pneumonia and Healthcare-Associated Pneumonia among Japanese Adults: Multicenter Study
Acronym Surveillance for Adult CAP and HCAP in Japan
Scientific Title Prospective Surveillance for Community-Acquired Pneumonia and Healthcare-Associated Pneumonia among Japanese Adults: Multicenter Study
Scientific Title:Acronym Surveillance for Adult CAP and HCAP in Japan
Region
Japan

Condition
Condition Pneumonia
Classification by specialty
Medicine in general Pneumology Infectious disease
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Primary objectives:
1)To estimate the incidence of CAP and HCAP among Japanese population.
2)To determine the etiology of adult pneumonia and the serotype distribution of Streptococcus pneumoniae isolates.

Secondary objectives:
1) To establish new laboratory techniques to identify pathogenic organisms from pneumonia patients.
2) To estimate the effectiveness of PPV against CAP among senior population.
3) To provide the baseline data for future PCV hard immunity study.
Basic objectives2 Others
Basic objectives -Others Epidemiology
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes 1) The incidence of CAP and HCAP among Japanese population
2) The etiology of adult pneumonia
3) The serotype distribution of Streptococcus pneumoniae isolates
Key secondary outcomes 1) New laboratory techniques to identify pathogenic organisms from pneumonia patients
2) The effectiveness of PPV against CAP among senior population
3) The baseline data for future PCV hard immunity study

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Inclusion criteria
All patients:
1) aged 15 years and over,
2) present to study hospitals with any clinical signs compatible with pneumonia, and
3) have consolidation on chest X-ray.

Key exclusion criteria Exclusion criteria
Hospital-acquired pneumonia (pneumonia developed after 48 hours of admission)
Ventilator-associated pneumonia (pneumonia developed under intubation or mechanical ventilation)
Target sample size 800

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Konosuke Morimoto
Organization Nagasaki University
Institute of Tropical Medicine
Division name Department of Clinical Medicine
Zip code
Address 1-12-4,Sakamoto,Nagasakishi,Nagasakiken
TEL 095-819-7842
Email komorimo@nagasaki-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Konosuke Morimoto
Organization Nagasaki University Institute of Tropical Medicine
Division name Department of Clinical Medicine
Zip code
Address 1-12-4,Sakamoto,Nagasakishi,Nagasakiken
TEL 095-819-7842
Homepage URL
Email komorimo@nagasaki-u.ac.jp

Sponsor
Institute Nagasaki University
Institute
Department

Funding Source
Organization Pfizer
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Chikamori Hospital, Kochi
Kameda Medical Center, Chiba
Ebetsu Municipal Hospital, Hokkaido
Jyuzenkai Hospital, Nagasaki
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人近森会近森病院(高知県)
医療法人鉄蕉会亀田総合病院(千葉県)
江別市立病院(北海道)
社会福祉法人 十善会病院(長崎)

Other administrative information
Date of disclosure of the study information
2011 Year 12 Month 31 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications http://www.ncbi.nlm.nih.gov/pubmed/25822890
Number of participants that the trial has enrolled
Results A total of 1,772 COP episodes out of 932,080 hospital visits were enrolled during the surveillance. The estimated overall incidence rates of adult COP, hospitalization, and in-hospital death were 16.9 (95% confidence interval, 13.6 to 20.9), 5.3 (4.5 to 6.2), and 0.7 (0.6 to 0.8) per 1,000 person-years (PY), respectively. The incidence rates sharply increased with age.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2011 Year 09 Month 20 Day
Date of IRB
Anticipated trial start date
2012 Year 01 Month 01 Day
Last follow-up date
2014 Year 09 Month 30 Day
Date of closure to data entry
2015 Year 03 Month 31 Day
Date trial data considered complete
2015 Year 03 Month 31 Day
Date analysis concluded

Other
Other related information The estimated annual number of adult COP cases in the entire Japanese population was 1,880,000. Aspiration-associated pneumonia (630,000) was the leading etiologic category, followed by Streptococcus pneumoniae-associated pneumonia (530,000), Haemophilus influenzae-associated pneumonia (420,000), and respiratory virus-associated pneumonia (420,000), including influenza-associated pneumonia (30,000).

Management information
Registered date
2011 Year 12 Month 19 Day
Last modified on
2016 Year 08 Month 22 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008166

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.